Pharmaceutical Industry Today
Hereditary Angioedema Market Examined In New Market Research Report
credenceresearch.com has Published New Research Report Title “Global Hereditary Angioedema Market Report 2017 to 2025" Market Research Report To Their Database
Published 19 September 2018
The latest market report published by Credence Research, Inc. “Hereditary Angioedema Market was valued at US$ 1,750.2 Mn in 2016, and is expected to reach US$ 3,689.4 Mn by 2025 expanding at a CAGR of 8.19% from 2017 to 2025.
The purpose of the report is to illustrate the state of the market of Hereditary Angioedema, to present actual information about the volumes of production, exports, imports, consumption and the state of the market, the changes that took place in 2017, and also, to build a forecast for the growth of the industry in the medium term until 2025.
Market Insights:
Hereditary angioedema is a rare autosomal dominant disorder and has disease epidemiology of one individual per 10,000 - 50,000 without major sex or ethnic differences. Hereditary angioedema has resulted in tremendous humanistic burden on patients in terms of poor physical and mental health causing a major setback on education, career, work productivity and socioeconomic impediment. Introduction of disease specific treatment drugs in the past decade has improved patients’ quality of life and reduced the cost related to hospitalization.
In 2016, C1 esterase inhibitors segment dominated the market due to the recent approval of novel drugs: Berinert and Haegarda. Additionally, technological advancement in drug delivery (for e.g. Haegarda is the only medication available as a subcutaneous treatment option). Kallikrein inhibitors is expected to be the fastest growing segment throughout the forecast period 2017-2025, majorly due to increasing incidences in patients with severe angioedema anaphylactic shock and promising product pipeline, touted to offer better results than the existing treatment options. The drug in Phase III DX 2930 has received breakthrough therapy designation and orphan drug designation by the USFDA. Phase II drug BCX-7353 is an oral preparation to counteract the severe swelling attacks in the intestinal and airway tract.
Browse here for full report with Toc: https://www.credenceresearch.com/report/hereditary-angioedema-market
Leading Players:
This report is the result of an extensive survey drawn from Credence Research’s exclusive panel of leading global market industry executives; it provides data and analysis on buyer investment, acquisition, and developments within the global market research. It includes key topics such as global Hereditary Angioedema buyer expenditure and procurement behaviors and strategies and recognizes the threats and possibilities within the industry, economic outlook trends, and business confidence within global industry executives. Most secondary research reports are based on general industry drivers and do not understand the industry executives’ attitude and changing behaviors, creating a gap in presenting the business outlook of the industry; in an effort to bridge this gap, Credence Research created this primary research-based report by gathering the opinions of multiple stakeholders in the value chain of the global industry.
Download Free Request Checkout: https://www.credenceresearch.com/checkout/58675
What is the current market landscape and what is changing?
Executives from the global industry anticipate an increase in levels of consolidation, with 55% of respondents projecting an increase in merger and acquisition (M&A) activities in 2017.
The report on the market of Hereditary Angioedema contains:
Analysis and forecast of Hereditary Angioedema market dynamics;
Analysis of domestic production, market shares of the main market players;
Analysis of exports and imports;
Analysis of factors, leading the development of the Hereditary Angioedema market;
Assessment and forecast of Hereditary Angioedema market development;
Financial and business profiles of the leading companies in the Hereditary Angioedema industry.
Also you can request us for sample in pdf with more details and graph: https://www.credenceresearch.com/sample-request/58675
Scope
- Up to date working Hereditary Angioedema data by major regions in the world, the forecast of planned capacity additions by 2026
- The annual breakdown of capital expenditure spending on proposed Hereditary Angioedema for the period 2018 to 2026
- Planned Hereditary Angioedema additions and capital expenditure spending by key countries and companies across the world
- Planned capital expenditure spending on new Hereditary Angioedema projects by region, key countries, and companies
- Details of major planned Hereditary Angioedema projects in the world up to 2026
Our Blogs: http://www.technicaltop.com/2017/09/19/global-hereditary-angioedema-market-industry-analysis-size-share-growth-trends-outlook-and-forecast-2017-to-2025/
http://www.mobilecomputingtoday.co.uk/6524/hereditary-angioedema-market-expected-reach-3689-4-2025-credence-research/
The purpose of the report is to illustrate the state of the market of Hereditary Angioedema, to present actual information about the volumes of production, exports, imports, consumption and the state of the market, the changes that took place in 2017, and also, to build a forecast for the growth of the industry in the medium term until 2025.
Market Insights:
Hereditary angioedema is a rare autosomal dominant disorder and has disease epidemiology of one individual per 10,000 - 50,000 without major sex or ethnic differences. Hereditary angioedema has resulted in tremendous humanistic burden on patients in terms of poor physical and mental health causing a major setback on education, career, work productivity and socioeconomic impediment. Introduction of disease specific treatment drugs in the past decade has improved patients’ quality of life and reduced the cost related to hospitalization.
In 2016, C1 esterase inhibitors segment dominated the market due to the recent approval of novel drugs: Berinert and Haegarda. Additionally, technological advancement in drug delivery (for e.g. Haegarda is the only medication available as a subcutaneous treatment option). Kallikrein inhibitors is expected to be the fastest growing segment throughout the forecast period 2017-2025, majorly due to increasing incidences in patients with severe angioedema anaphylactic shock and promising product pipeline, touted to offer better results than the existing treatment options. The drug in Phase III DX 2930 has received breakthrough therapy designation and orphan drug designation by the USFDA. Phase II drug BCX-7353 is an oral preparation to counteract the severe swelling attacks in the intestinal and airway tract.
Browse here for full report with Toc: https://www.credenceresearch.com/report/hereditary-angioedema-market
Leading Players:
- BioCryst Pharmaceuticals, Inc.
- Business Description
- Financial Information (Subject to data availability)
- Product Portfolio
- Key Developments
- Cipla, Inc.
- CSL Behring Ltd.
- Ionis Pharmaceuticals, Inc.
- iBio, Inc.
- Merck & Co., Inc.
- Pharming Group NV
- Sanofi N.V.
- Shire plc.
- Teva Pharmaceutical Industries, Ltd.
- Other Notable Players
This report is the result of an extensive survey drawn from Credence Research’s exclusive panel of leading global market industry executives; it provides data and analysis on buyer investment, acquisition, and developments within the global market research. It includes key topics such as global Hereditary Angioedema buyer expenditure and procurement behaviors and strategies and recognizes the threats and possibilities within the industry, economic outlook trends, and business confidence within global industry executives. Most secondary research reports are based on general industry drivers and do not understand the industry executives’ attitude and changing behaviors, creating a gap in presenting the business outlook of the industry; in an effort to bridge this gap, Credence Research created this primary research-based report by gathering the opinions of multiple stakeholders in the value chain of the global industry.
Download Free Request Checkout: https://www.credenceresearch.com/checkout/58675
What is the current market landscape and what is changing?
Executives from the global industry anticipate an increase in levels of consolidation, with 55% of respondents projecting an increase in merger and acquisition (M&A) activities in 2017.
The report on the market of Hereditary Angioedema contains:
Analysis and forecast of Hereditary Angioedema market dynamics;
Analysis of domestic production, market shares of the main market players;
Analysis of exports and imports;
Analysis of factors, leading the development of the Hereditary Angioedema market;
Assessment and forecast of Hereditary Angioedema market development;
Financial and business profiles of the leading companies in the Hereditary Angioedema industry.
Also you can request us for sample in pdf with more details and graph: https://www.credenceresearch.com/sample-request/58675
Scope
- Up to date working Hereditary Angioedema data by major regions in the world, the forecast of planned capacity additions by 2026
- The annual breakdown of capital expenditure spending on proposed Hereditary Angioedema for the period 2018 to 2026
- Planned Hereditary Angioedema additions and capital expenditure spending by key countries and companies across the world
- Planned capital expenditure spending on new Hereditary Angioedema projects by region, key countries, and companies
- Details of major planned Hereditary Angioedema projects in the world up to 2026
Our Blogs: http://www.technicaltop.com/2017/09/19/global-hereditary-angioedema-market-industry-analysis-size-share-growth-trends-outlook-and-forecast-2017-to-2025/
http://www.mobilecomputingtoday.co.uk/6524/hereditary-angioedema-market-expected-reach-3689-4-2025-credence-research/
Share on Social Media
Other Industry News
Ready to start publishing
Sign Up today!
